Price
Target price
€11.90
€11.90
0.850%
0.1
0.850%
€17.04
28.11.25 / Frankfurt
WKN: A1T7BJ / Symbol: ENTA / Name: Enanta / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Enanta Pharmaceuticals Inc. Stock
Enanta Pharmaceuticals Inc. gained 0.850% compared to yesterday.
Enanta Pharmaceuticals Inc. is currently one of the favorites of our community with 9 Buy predictions and no Sell predictions.
With a target price of 17 € there is a positive potential of 42.86% for Enanta Pharmaceuticals Inc. compared to the current price of 11.9 €.
So far the community has only identified positive things for Enanta Pharmaceuticals Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Enanta Pharmaceuticals Inc. in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Enanta Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals Inc. | 0.850% | 9.174% | 27.273% | 46.012% | 112.500% | -71.667% | -65.205% |
| Ardelyx Inc. | 0.360% | 7.699% | 1.483% | -6.465% | 1.994% | 207.319% | 0.957% |
| Krystal Biotech | 0.690% | 2.688% | 15.799% | 1.421% | 24.244% | 148.816% | - |
| Evolus Inc | -0.840% | 7.207% | 4.386% | -54.231% | -43.333% | -11.194% | 93.056% |
Comments
Enanta Pharmaceuticals (NASDAQ:ENTA) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $17.00 price target on the stock.
Show more
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock.
Show more
Ratings data for ENTA provided by MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock.
Show more
Ratings data for ENTA provided by MarketBeat